- Home
- PRFX vs ADTX Comparison
PRFX vs ADTX Comparison
Compare PRFX & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- ADTX
- Stock Information
- Founded
- PRFX 2007
- ADTX 2017
- Country
- PRFX Israel
- ADTX United States
- Employees
- PRFX N/A
- ADTX N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- ADTX Health Care
- Exchange
- PRFX Nasdaq
- ADTX Nasdaq
- Market Cap
- PRFX 3.6M
- ADTX 3.1M
- IPO Year
- PRFX 2020
- ADTX 2020
- Fundamental
- Price
- PRFX $1.39
- ADTX $1.39
- Analyst Decision
- PRFX Hold
- ADTX
- Analyst Count
- PRFX 1
- ADTX 0
- Target Price
- PRFX N/A
- ADTX N/A
- AVG Volume (30 Days)
- PRFX 185.8K
- ADTX 1.2M
- Earning Date
- PRFX 08-14-2025
- ADTX 08-18-2025
- Dividend Yield
- PRFX N/A
- ADTX N/A
- EPS Growth
- PRFX N/A
- ADTX N/A
- EPS
- PRFX N/A
- ADTX N/A
- Revenue
- PRFX N/A
- ADTX $55,323.00
- Revenue This Year
- PRFX N/A
- ADTX $15,768.94
- Revenue Next Year
- PRFX N/A
- ADTX N/A
- P/E Ratio
- PRFX N/A
- ADTX N/A
- Revenue Growth
- PRFX N/A
- ADTX N/A
- 52 Week Low
- PRFX $1.25
- ADTX $1.28
- 52 Week High
- PRFX $16.63
- ADTX $27,200.00
- Technical
- Relative Strength Index (RSI)
- PRFX 33.95
- ADTX 44.87
- Support Level
- PRFX $1.25
- ADTX $1.28
- Resistance Level
- PRFX $1.76
- ADTX $2.19
- Average True Range (ATR)
- PRFX 0.10
- ADTX 0.15
- MACD
- PRFX -0.05
- ADTX 0.08
- Stochastic Oscillator
- PRFX 23.53
- ADTX 30.77
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.